Mylan overhaul of West Virginia plant has a ways to go
While Mylan’s third quarter results impressed analysts, the generics drugmaker is still dealing with some significant manufacturing issues, some of them not of its own making. Its adjusted earnings per share beat analyst expectations to land at $ 1.25 during the quarter, representing a 14% year-over-year increase. “We see Mylan as one of the better-positioned… Read More »